H. Loor

发表

Does the biomarker 15N-lactose ureide allow to estimate the site of fermentation of resistant starch?

P. Rutgeerts, K. Verbeke, V. Preter, 2008, European journal of nutrition.

In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation

D. Kuypers, P. Annaert, T. Vanhove, 2018, Basic & clinical pharmacology & toxicology.

In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine‐Treated as Compared With Tacrolimus‐Treated Renal Allograft Recipients

K. Verbeke, D. Kuypers, Y. Vanrenterghem, 2011, Clinical pharmacology and therapeutics.

Fk506&reduces&neuroinflammation&and&dopaminergic& Neurodegeneration&in&an&α8synuclein8based&rat&model&for& Parkinson's&disease.% Fk506 Reduces Neuroinflammation and Dopaminergic Neurodegeneration in an - Synuclein-based Rat Model for Parkinson's Disease Authors

V. Baekelandt, C. Van den Haute, M. Carlon, 2022 .

The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients

L. Elens, R. H. Schaik, D. Kuypers, 2014, The Pharmacogenomics Journal.

Impact of hypoalbuminemia on voriconazole pharmacokinetics in adult critically ill

P. Annaert, I. Spriet, K. Lagrou, 2014 .

In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

K. Verbeke, D. Kuypers, Y. Vanrenterghem, 2012, Clinical pharmacology and therapeutics.

In Vivo CYP3A4-Activity, CYP3A5-Genotype and Hematocrit Predict Tacrolimus Dose-Requirements and Clearance in Renal Transplant Recipients: 2026

K. Verbeke, D. Kuypers, Y. Vanrenterghem, 2012 .

Albumin is the main plasma binding protein for indoxyl sulfate and p‐cresyl sulfate

P. Annaert, B. Meijers, P. Evenepoel, 2013, Biopharmaceutics & drug disposition.

Fexofenadine, a Putative In Vivo P‐glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients

T. Bouillon, H. de Loor, P. Annaert, 2017, Clinical pharmacology and therapeutics.

FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease

V. Baekelandt, M. Carlon, R. Gijsbers, 2015, Neurobiology of Aging.

Response to ‘Tacrolimus pharmacokinetics after kidney transplantation – Influence of changes in haematocrit and steroid dose’

K. Verbeke, D. Kuypers, T. Vanhove, 2015, British journal of clinical pharmacology.

PHARMACOKINETICS Comparative performance of oral midazolam clearance and plasma 4 β -hydroxycholesterol to explain interindividual variability in tacrolimus clearance

D. Kuypers, P. Annaert, U. Diczfalusy, 2016 .